Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

Leal JF, Martinez-Diez M, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, Garcia-Fernandez LF, Galmarini CM (2010) PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol 161(5):1099–1110

Bueren-Calabuig JA, Giraudon C, Galmarini CM, Egly JM, Gago F (2011) Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res 39(18):8248–8257. doi:10.1093/nar/gkr512

Santamaria G, Martínez-Leal JF, Cuevas C, Garcia-Fernandez LF, Galmarini CM Lurbinectedin (PM01183) specifically targets RNA Pol II for degradation via the proteasome pathway in a transcription and TC-NER dependent fashion. Eur J Cancer 50:20. doi:10.1016/S0959-8049(14)70173-x

Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE, Larsen AK (2011) Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 10(8):1481–1489. doi:10.1158/1535-7163.MCT-11-0252

Santamaria Nunez G, Robles CM, Giraudon C, Martinez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM (2016) Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells. Mol Cancer Ther. doi:10.1158/1535-7163.mct-16-0172

Guillen MJ, Cataluña O, Palomares M, Lopez R, Cuevas C, Aviles P (2011) In vivo combination studies of PM01183 with alkylating, antimetabolites, DNA-topoisomerase inhibitors and tubulin binding agents. Cancer Res 71 (8 Suppl):Abstract 3538

Soares DG, Larsen AK, Escargueil AE (2012) The DNA damage response to monofunctional anticancer DNA binders. Drug Discov Today 9(2):59–67

Aviles P, Galmarini C, Cuevas C, Guillen MJ, Frapolli R, Uboldi S, Romano M, Tavecchio M, Erba E, Bello E, D'Incalci M (2009) Mechanism of action and antitumor activity of PM01183. Cancer Res 69(9 Suppl):Abstract 2679

Mangues R, Céspedes MV, Guillén MJ, Alamo P, López R, Gallardo A, Nuñez P, Cuevas C, Aviles P 223 Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor Xenografts. Eur J Cancer 48:67–68. doi:10.1016/S0959-8049(12)72021-X

Cespedes MV, Guillen MJ, Lopez-Casas PP, Sarno F, Gallardo A, Alamo P, Cuevas C, Hidalgo M, Galmarini CM, Allavena P, Aviles P, Mangues R (2016) Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its in vivo synergism with gemcitabine. Dis Model Mech. doi:10.1242/dmm.026369

Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 9:216. doi:10.1186/1479-5876-9-216

Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ (2014) First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res: an Off J Am Assoc Cancer Res 20(8):2205–2214. doi:10.1158/1078-0432.CCR-13-1880

Ratain MJ, Gore L, Szyldergemajn S, Diamond J, Geary D, Fernandez-Teruel C, Soto-Matos A, Sharma M, Jimeno A 23 Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumors. Eur J Cancer 50:13–14. doi:10.1016/S0959-8049(14)70149-2

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. doi:10.1200/jco.2015.62.3488

Yilmaz B, Kadioglu YY, Aksoy Y (2004) Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography. Anal Biochem 332(2):234–237. doi:10.1016/j.ab.2004.05.059

Messersmith WA, Jimeno A, Ettinger D, Laheru D, Brahmer J, Lansey D, Khan Y, Donehower RC, Elsayed Y, Zannikos P, Hidalgo M (2008) Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 63(1):181–188. doi:10.1007/s00280-008-0733-7

Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol: Off J Eur Soc Med Oncol/ ESMO 13(9):1479–1489

Lee M-Y, Jung KS, Kim HS, Lee JY, Lim SH, Kim M, Jung HA, Kim SM, Sun JM, Ahn M-J, Lee J, Park SH, Yi SY, Hwang IG, Lee S-C, Ahn HK, Lim DH, Lee SI, Park KW (2015) Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World J Gastroenterol 21(14):4268–4274. doi:10.3748/wjg.v21.i14.4268

Seidman AD (2004) Gemcitabine and docetaxel in metastatic breast cancer. Oncology (Williston Park) 18(14 Suppl 12):13–16

Johnson DH (2001) Gemcitabine for the treatment of non-small-cell lung cancer. Oncology (Williston Park) 15(3 Suppl 6):33–39

Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62(1):2–8

Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck HJ, Rochon J, Zimmermann AH, Eisenhauer E, Ago O, Ncic CTG, Eortc GCG (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699–4707. doi:10.1200/JCO.2006.06.0913

Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nistico C, Terzoli E, Cognetti F, Giannarelli D (2007) Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 110(3):525–533. doi:10.1002/cncr.22809

Stinchcombe TE, Socinski MA (2008) Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13(Suppl 1):28–36. doi:10.1634/theoncologist.13-S1-28

He J, Hu Y, Hu M, Li B (2015) Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 5:13110. doi:10.1038/srep13110

Cameron L, Solomon B (2015) Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. Drugs 75(10):1059–1070. doi:10.1007/s40265-015-0415-9

Poveda A, Berton-Rigaud D, Ray-Coquard IL, Alexandre J, Provansal M, Soto A, Kahatt CM, Szyldergemajn SA, Nieto A, Fernandez C, Guerra Alia E, Casado A, Gonzalez-Martin A, Del Campo JM (2014) Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study. ASCO Meeting Abstracts 32(15_suppl):5505

Balmaña J, Cruz C, Garber J, Perez Fidalgo JA, Lluch A, Tung N, Antolin S, Fernandez C, Kahatt C, Szyldergemajn S, Soto Matos A, Extremera S, Baselga J, Isakoff SJ (2015) Abstract P3–13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial. Cancer Res 75(9 Supplement):P3–13-01. doi:10.1158/1538-7445.sabcs14-p3-13-01